drug
cevidoplenib
Phase 2updated 3mo agoby Genosco Inc
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
News(1)
- Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million upfront for exclusive global rights to Oscotec’s next-generation SYK inhibitor, called cevidoplenib. The South…endpoints · 2mo ago
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that